. "N\u00E1dorov\u00E9 markery u karcinomu prostaty, bl\u00FDsk\u00E1 se na lep\u0161\u00ED \u010Dasy"@cs . . "[3CD968F0A0C4]" . "12" . "Praktick\u00FD l\u00E9ka\u0159" . . . "Tumour markers in prostate cancer. A new horizont"@en . "N\u00E1dorov\u00E9 markery u karcinomu prostaty, bl\u00FDsk\u00E1 se na lep\u0161\u00ED \u010Dasy" . "381469" . "1"^^ . "P(1M0508), V, Z(AV0Z40550506)" . . . "Zachoval, Roman" . "RIV/00216208:11120/08:00003034!RIV12-MSM-11120___" . "4"^^ . . "3"^^ . . "11120" . . "Vik, Viktor" . . . "Nejpou\u017E\u00EDvan\u011Bj\u0161\u00EDm n\u00E1dorov\u00FDm markerem u karcinomu prostaty je od konce 80-t\u00FDch let PSA (prostatick\u00FD specifick\u00FD antigen). Jeho zaveden\u00ED do klinick\u00E9 praxe zcela zm\u011Bnilo nejen diagnostiku, ale i celou terapii karcinomu prostaty. Hlavn\u00EDm nedostatkem se uk\u00E1zala org\u00E1nov\u00E1 a nikoliv n\u00E1dorov\u00E1 specifika. Snahou posledn\u00EDch let je nal\u00E9zt biomarker, kter\u00FD je produkov\u00E1n pouze bu\u0148kou n\u00E1dorovou a nikoli bu\u0148kou nebo org\u00E1nem jako takov\u00FDm. V lo\u0148sk\u00E9m roce byly publikov\u00E1ny prvn\u00ED klinick\u00E9 zku\u0161enosti s EPCA-2 (early prostate cancer antigen - 2), jeho\u017E specifika i senzitivita jasn\u011B p\u0159ed\u010D\u00ED dosavadn\u00ED zku\u0161enosti s PSA. V\u00FDvoj ale pokra\u010Duje d\u00E1le a objevuj\u00ED se dal\u0161\u00ED medicinsky mimo\u0159\u00E1dn\u011B zaj\u00EDmav\u00E9 molekuly jako nap\u0159. PSMA (prostatick\u00FD specifick\u00FD membr\u00E1nov\u00FD antigen) respektive GCPII (glutam\u00E1tkarboxypeptid\u00E1za II) v jeho\u017E v\u00FDzkumu byl v posledn\u00EDch deseti letech zaznamen\u00E1n z\u00E1sadn\u00ED posun. V sou\u010Dasn\u00E9 dob\u011B lze konstatovat, \u017Ee GCPII, respektive PSMA p\u0159edstavuje vysoce specifick\u00FD n\u00E1dorov\u00FD marker pro karcinom prostaty s jasnou korelac\u00ED k agresiv" . . . "N\u00E1dorov\u00E9 markery u karcinomu prostaty, bl\u00FDsk\u00E1 se na lep\u0161\u00ED \u010Dasy" . "0032-6739" . "PSA has been the most commonly used prostate cancer marker since the end of the 1980s. Its introduction into clinical practice has changed prostate cancer diagnosis and treatment dramatically. The major disadvantage with PSA is its organ specificity and not cancer specificity. The major research task in recent years has been an attempt to define a biomarker that is produced specifically by the cancer cell only. The first clinical experience with EPCA-2 was published last year. It is clear that its specificity and sensitivity are better than for PSA. Nevertheless, the research has been ongoing and new molecules which are very interesting from a medical point of view have been discovered. One of which is PSMA (GCP II) and major progress towards understanding the function of this enzyme has been made in the past ten years. Currently, it can be stated that GCP II (PSMA) is a highly specific tumour marker for prostate cancer, which correlates with differentiation of the tumour and has prognostic potential."@en . "Nejpou\u017E\u00EDvan\u011Bj\u0161\u00EDm n\u00E1dorov\u00FDm markerem u karcinomu prostaty je od konce 80-t\u00FDch let PSA (prostatick\u00FD specifick\u00FD antigen). Jeho zaveden\u00ED do klinick\u00E9 praxe zcela zm\u011Bnilo nejen diagnostiku, ale i celou terapii karcinomu prostaty. Hlavn\u00EDm nedostatkem se uk\u00E1zala org\u00E1nov\u00E1 a nikoliv n\u00E1dorov\u00E1 specifika. Snahou posledn\u00EDch let je nal\u00E9zt biomarker, kter\u00FD je produkov\u00E1n pouze bu\u0148kou n\u00E1dorovou a nikoli bu\u0148kou nebo org\u00E1nem jako takov\u00FDm. V lo\u0148sk\u00E9m roce byly publikov\u00E1ny prvn\u00ED klinick\u00E9 zku\u0161enosti s EPCA-2 (early prostate cancer antigen - 2), jeho\u017E specifika i senzitivita jasn\u011B p\u0159ed\u010D\u00ED dosavadn\u00ED zku\u0161enosti s PSA. V\u00FDvoj ale pokra\u010Duje d\u00E1le a objevuj\u00ED se dal\u0161\u00ED medicinsky mimo\u0159\u00E1dn\u011B zaj\u00EDmav\u00E9 molekuly jako nap\u0159. PSMA (prostatick\u00FD specifick\u00FD membr\u00E1nov\u00FD antigen) respektive GCPII (glutam\u00E1tkarboxypeptid\u00E1za II) v jeho\u017E v\u00FDzkumu byl v posledn\u00EDch deseti letech zaznamen\u00E1n z\u00E1sadn\u00ED posun. V sou\u010Dasn\u00E9 dob\u011B lze konstatovat, \u017Ee GCPII, respektive PSMA p\u0159edstavuje vysoce specifick\u00FD n\u00E1dorov\u00FD marker pro karcinom prostaty s jasnou korelac\u00ED k agresiv"@cs . . "PSMA; GCPII; prostate cancer"@en . "N\u00E1dorov\u00E9 markery u karcinomu prostaty, bl\u00FDsk\u00E1 se na lep\u0161\u00ED \u010Dasy"@cs . . "CZ - \u010Cesk\u00E1 republika" . "Tumour markers in prostate cancer. A new horizont"@en . . "88" . "RIV/00216208:11120/08:00003034" . . .